Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook

Oxford BioMedica Plc OXBDF has raised its forecast for cumulative revenues from AstraZeneca Plc AZN by the end of 2021 to more than £100 million from £50 million pounds earlier.
The company did not provide any other details on its deal.
Oxford BioMedica also expects significant growth in Group Operating EBITDA in the year ending 2021.
AstraZeneca will purchase additional batches of Oxford BioMedica's COVID-19 vaccine in the second half of 2021, after successfully manufacturing large-scale batches of AstraZeneca's vaccine.
Oxford BioMedica announced an 18 month supply agreement in September 2020 under a three-year supply and development agreement with AstraZeneca for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.
Price Action: AZN shares are up 0.57% at $56.20, and OXBDF shares are up 10.6% at $15.75 on the last check Tuesday.